LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
DexCom is building increasingly user-friendly devices that continuously monitor blood glucose levels, and a new collaboration between DexCom and Google could lead to the smallest such devices yet.
Oppenheimer also removed its $102.00 price target on the Company’s stock. Oppenheimer cited, among other things, patient concern with the G7’s poor accuracy, failed sensor insertions, abrupt stoppages ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results